Targeted C1q Inhibition Technology: Annexon's proprietary antibodies specifically block C1q, a key initiator of the classical complement pathway, offering a novel and potentially more precise therapeutic approach than broader complement inhibitors.

Pioneering First-in-Class Therapies: As a leader in C1q inhibition, Annexon is developing therapies that could be first-in-class for multiple severe neurodegenerative, autoimmune, and ophthalmic conditions, addressing unmet needs with a unique mechanism.

Diverse Pipeline Addressing Unmet Needs: With candidates targeting Guillain-Barré Syndrome (GBS), Huntington's Disease (HD), and Geographic Atrophy (GA), Annexon's pipeline addresses severe conditions with limited treatment options, diversifying market opportunities and impact.